Aurora Investment Counsel’s Neurocrine Biosciences NBIX Stock Holding History

Aurora Investment Counsel’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34M	Sell	10,201 -614	-6%	-$81.5K	0.75%	73
2025 Q4	$1.53M	Sell	10,815 -23	-0.2%	-$3.33K	0.81%	68
2025 Q3	$1.52M	Sell	10,838 -189	-2%	-$25.6K	0.8%	69
2025 Q2	$1.39M	Buy	11,027 +507	+5%	+$58.1K	0.73%	74
2025 Q1	$1.16M	Buy	10,520 +138	+1%	+$17.5K	0.65%	79
2024 Q4	$1.42M	Sell	10,382 -63	-0.6%	-$7.79K	0.78%	67
2024 Q3	$1.2M	Buy	10,445 +8	+0.1%	+$1.1K	0.65%	82
2024 Q2	$1.44M	Sell	10,437 -118	-1%	-$16.2K	0.84%	68
2024 Q1	$1.46M	Sell	10,555 -3,171	-23%	-$433K	0.83%	68
2023 Q4	$1.45M	Buy	13,726 +342	+3%	+$39.4K	0.94%	53
2023 Q3	$1.51M	Sell	13,384 -124	-0.9%	-$13.1K	1%	39
2023 Q2	$1.27M	Sell	13,508 -151	-1%	-$14.8K	0.82%	64
2023 Q1	$1.38M	Buy	+13,659	New	+$1.42M	0.9%	56

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aurora Investment Counsel's NBIX Position: Q1 2026 in Review

Aurora Investment Counsel reduced its Neurocrine Biosciences (NBIX) stake by 5.7% in Q1 2026, selling an estimated $81.5K and leaving 10,201 shares worth $1.34M. The position accounts for 0.75% of the portfolio, ranked #73.

Aurora Investment Counsel first reported a position in NBIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.53M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Aurora Investment Counsel held 10,201 shares of Neurocrine Biosciences worth $1.34M as of Q1 2026.
Aurora Investment Counsel sold 614 Neurocrine Biosciences shares in Q1 2026, an estimated $81.5K.
Neurocrine Biosciences made up 0.75% of Aurora Investment Counsel's portfolio in Q1 2026, its #73 holding.
Aurora Investment Counsel first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 13 quarters since.
Aurora Investment Counsel's Neurocrine Biosciences position peaked at $1.53M in Q4 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Aurora Investment Counsel's 13F filing for Q1 2026, filed 6 May 2026.